OBJECTIVE: To explore the intervention of compound Kushen injection combined with gefitinib on hypercoagulable state in patients with advanced non-small cell lung adenocarcinoma. METHODS: Ninety patients with non-small cell lung adenocarcinoma who were biochemical reported as hypercoagulable state in Center Hospital of Liaoyang from Jun. 2018 to May 2021 were randomly divided into the observation group and the control group

with 45 cases in each group. Patients in the two groups were treated with gefitinib

the observation group was given compound Kushen injection for 2 weeks（14 d） as a course

and both groups were treated with 4 courses. Coagulation changes [plasma prothrombin time（PT）

activated partial thromboplastin time（APTT）

prothrombin time（TT） and fibrinogen（FIB）]

coagulation metabolite changes [D-dimer

fibrin degradation product（FDP）

platelet count（PLT）

platelet pressure product（PCT） and platelet aggregation rate（PAg）]

hemodynamic indicators（erythrocyte aggregation indicator

hematocrit

capillary plasma viscosity

whole blood viscosity low shearing and whole blood viscosity high shearing） before and after treatment in two groups were observed

the incidence of adverse drug reactions was recorded. RESULTS: After treatment

the PT

APTT and FIB levels in the observation group were higher than those in the control group

while the TT in the observation group was shorter than that in the control group

and there were significant differences in the levels of APTT

TT between the two groups（P<0.05）;the levels of D-dimer

FDP

PLT

PCT and PAg in the observation group were lower than those in the control group

and there were significant differences in the levels of D-dimer

FDP and PAg between the two groups（P<0.05）;the hemodynamic indicators（erythrocyte aggregation indicator

hematocrit

capillary plasma viscosity

whole blood viscosity low shearing and whole blood viscosity high shearing） of the observation group were significantly lower than the control group

the differences were statistically significant（P<0.05）. The incidence of adverse drug reactions in the observation group was 11.1%（5/45）

significantly lower than 31.1%（14/45） in the control group

with statistically significant differences（P<0.05）. CONCLUSIONS: For patients with non-small cell lung adenocarcinoma in hypercoagulable state

the combination of compound Kushen injection and gefitinib has significant therapeutic effect

and can improve the hypercoagulability of patients with non-small cell lung adenocarcinoma.